The global geriatric medicine market size was valued at USD 179.76 billion in 2025 and is projected to grow from USD 192.88 billion in 2026 to USD 338.91 billion by 2034, registering a CAGR of 7.3% during the forecast period from 2026 to 2034. North America dominated the geriatric medicine market with a market share of 38.45% in 2025.
Geriatric medicine is a specialized branch of medicine focused on the healthcare of elderly individuals, typically those aged 65 and above. It addresses the prevention, diagnosis, treatment, and management of diseases and disabilities common in older adults. Geriatricians consider the unique medical needs of aging patients, including multiple chronic conditions, cognitive decline, mobility issues, and polypharmacy. The goal is to improve quality of life, maintain functional independence, and provide holistic care through interdisciplinary approaches that often involve social, psychological, and environmental support alongside medical treatment.
Download a Free Sample To learn more about this report,
Remote Monitoring Is Expanding Into Home-Based Geriatric Care
The need to support older adults outside hospitals and long-term care facilities is increasing demand for remote monitoring and home-based digital health tools. This transition is combining wearable sensors, ambient monitoring, telehealth, and digital biomarkers to track mobility, activity, sleep, and other indicators, with a 2025 meta-analysis of 16 studies reporting pooled sensitivity of 78% and specificity of 79% for digital biomarkers in home-based frailty detection. More continuous monitoring can support earlier identification of functional changes and more proactive geriatric care at home.
AI Is Supporting Personalized Risk Assessment for Older Adults
The geriatric medicine market analysis shows that the complexity of aging, multimorbidity, and individual differences in functional decline is increasing demand for data-driven risk assessment in geriatric care. This transition is combining AI with clinical records, wearable data, and digital biomarkers to identify patterns linked to frailty and other health risks, while a 2025 meta-analysis of 23 digital-health studies involving 3,426 frail older adults found improvements in frailty status, grip strength, cognitive function, and quality of life with digital interventions. Personalized risk identification can help clinicians tailor monitoring and interventions to the changing needs of individual older adults.
Prevalence of Chronic Diseases Among Older Adults and Expansion of Geriatric Care Facilities and Specialized Clinics Drive Market
The higher prevalence of chronic diseases among older adults increases demand for geriatric medicines and specialized treatment as conditions such as diabetes, cardiovascular disease, arthritis, and dementia require long-term clinical management. Older patients with multiple chronic conditions, for example, may require regular medication, monitoring, and follow-up care across different specialties. This sustained treatment requirement supports recurring demand for geriatric medicines and healthcare services.
Expansion of geriatric care facilities and specialized clinics increases demand for medicines, diagnostic services, rehabilitation, and other products designed for older patients. Dedicated geriatric clinics, for example, can provide coordinated care for patients requiring medication management, mobility support, and treatment of age-related conditions. This broader care infrastructure increases patient access to specialized services and supports procurement across the geriatric healthcare ecosystem.
Shortage of Geriatric Specialists and Skilled Healthcare Professionals and High Cost of Geriatric Healthcare and Long-Term Treatment Restrain Market Expansion
Shortage of geriatric specialists and skilled healthcare professionals can limit access to specialized diagnosis, treatment, medication management, and long-term care for older adults. Limited specialist availability can reduce treatment capacity and make comprehensive geriatric care difficult to provide in underserved areas. Consequently, workforce shortages can slow adoption of specialized services and constrain market expansion.
High cost of geriatric healthcare and long-term treatment can increase the financial burden associated with medicines, regular consultations, monitoring, and supportive care. Higher treatment expenses can limit access for patients with restricted healthcare budgets and reduce adherence to long-term treatment plans.
Geriatric Medicine for Post-Acute Care and Medication Management Services and Preventive Geriatric Wellness Programs Offers Growth Opportunities
Hospitals, rehabilitation centers, skilled nursing facilities, and elderly patients are key customers for specialized post-acute care and medication management services that support recovery after hospitalization. Companies such as CVS Health can expand revenue through medication review, care coordination, pharmacy services, and partnerships with healthcare providers.
Senior living communities, wellness providers, and older adults are key customers for preventive programs focused on nutrition, mobility, cognitive wellness, and healthy aging. Companies such as Abbott can generate revenue through specialized nutrition products, wellness programs, and partnerships with senior care organizations, contributing to geriatric medicine market growth.
Polypharmacy and Drug Interaction Risks and Complexity of Managing Multiple Chronic Conditions Hinder Growth
Geriatric patients often use multiple medications simultaneously, increasing the risk of drug interactions, adverse reactions, and medication-related complications. This requires additional medication review and monitoring, increasing treatment complexity for healthcare providers and making it more difficult to implement standardized geriatric treatment pathways.
Managing multiple chronic conditions requires coordinated treatment plans that account for interactions between diseases, medications, and clinical priorities. This complexity can increase care coordination requirements and make treatment decisions more resource-intensive, limiting the scalability of standardized therapies and integrated geriatric care models.
The antihypertensives segment accounted for a market share of 18.4% in 2025 due to the high prevalence of hypertension among older adults and the continued need for long-term blood pressure management. Regular use of antihypertensive medicines supports sustained demand within geriatric care as cardiovascular risk increases with age.
The antidiabetics segment is expected to grow at a CAGR of 8.26% during the forecast period 2026-2034, driven by the increasing prevalence of diabetes among the aging population and the need for long-term glycemic management. Continued use of oral and injectable antidiabetic therapies supports demand for medicines designed to manage diabetes-related complications in older adults.
The analgesics segment is supported by the frequent occurrence of chronic pain and musculoskeletal conditions among older adults. Continued treatment of arthritis, neuropathic pain, and other age-related conditions sustains demand for pain management therapies. The statins segment benefits from their use in managing elevated cholesterol and reducing cardiovascular risk among older adults. Long-term lipid management supports consistent demand for statin therapies within geriatric healthcare. The proton pump inhibitor segment is supported by the treatment of acid-related gastrointestinal conditions, including gastroesophageal reflux disease and peptic disorders, which are common considerations in older populations. Continued medication use and management of gastrointestinal symptoms support demand for proton pump inhibitors.
The anticoagulant segment is driven by the need to prevent and manage blood clots in older adults with conditions such as atrial fibrillation and venous thromboembolism. Long-term anticoagulation therapy supports continued demand as cardiovascular and thromboembolic risks increase with age. The antipsychotic segment is used in the management of certain psychiatric and behavioral symptoms associated with conditions affecting older adults. Demand is linked to clinical needs involving dementia-related behavioral symptoms and other psychiatric disorders, subject to careful medical supervision. The antidepressant segment is supported by the treatment of depression and other mood disorders among older adults. Ongoing management of mental health conditions contributes to demand for antidepressant therapies within geriatric care.
Request Customizationto receive a tailored report.
The cancer segment is expected to grow at a CAGR of 8.31% during the forecast period 2026-2034, driven by the increasing prevalence of cancer among older adults and the need for long-term diagnosis, treatment, and supportive care. Advances in targeted therapies, immunotherapies, and personalized treatment approaches support demand for cancer medicines and specialized geriatric oncology care.
The cardiovascular segment accounted for a market share of 27.3% in 2025 due to the high prevalence of cardiovascular conditions among the aging population and the need for continuous disease management. Long-term treatment for hypertension, heart disease, and related conditions supports sustained demand for cardiovascular medicines and geriatric care. The arthritis segment is supported by the high incidence of joint degeneration and chronic musculoskeletal conditions among older adults. Ongoing management through analgesics, anti-inflammatory therapies, and other treatments sustains demand for geriatric medicines addressing mobility and pain-related conditions.
The neurological segment benefits from the increasing need to manage age-associated neurological disorders, including dementia, Parkinson’s disease, and other neurodegenerative conditions. Long-term treatment and supportive care requirements contribute to sustained demand for neurological therapies in geriatric populations. The osteoporosis segment is driven by the higher risk of bone loss and fractures among older adults, particularly with advancing age. Demand for therapies that support bone density and reduce fracture risk contributes to continued use of osteoporosis medicines in geriatric care. The respiratory segment is supported by the prevalence of chronic respiratory conditions among older adults and the need for ongoing symptom management. Long-term treatment of conditions such as chronic obstructive pulmonary disease and asthma sustains demand for respiratory medicines and related geriatric care.
The hospital pharmacies segment accounted for a market share of 42.6% in 2025 due to the high volume of prescriptions and medication dispensing associated with inpatient and outpatient geriatric care. Direct access to prescribed medicines within healthcare facilities supports medication availability and continuity of treatment for older patients.
The online pharmacies segment is expected to grow at a CAGR of 9.64% during the forecast period 2026-2034, driven by increasing adoption of digital healthcare services and the convenience of home delivery for older adults and their caregivers. Online platforms also support prescription-based medicine ordering and recurring purchases, improving accessibility to long-term therapies.
The retail pharmacies segment is supported by its broad geographic availability and convenient access to prescription and over-the-counter medicines for older adults. Pharmacist guidance, immediate product availability, and proximity to residential areas contribute to continued use of retail pharmacies for routine medication needs.
Speak to an Analystto discuss market opportunities.
The North America geriatric medicine market accounted for the largest regional share of 38.45% in 2025, supported by demographic ageing, with the U.S. Census Bureau projecting adults aged 65 and older to represent 23.4% of the U.S. population by 2060, while the 65+ population already increased to 64.6 million in 2025, expanding the patient base requiring geriatric healthcare and medicines.
The US geriatric medicine market will benefit from continued population ageing, with the U.S. Census Bureau projecting adults aged 65 and older to reach 73.2 million by 2030, representing 20.6% of the population, while adults aged 85 and older are projected to increase to 9.9 million by 2030, expanding demand for medicines addressing age-related conditions. The Canada geriatric medicine market will see a larger addressable elderly population, with Statistics Canada projecting the share of Canadians aged 65 and older to reach 22.6%-32.5% by 2075 across its slow-aging to fast-aging scenarios, while the population aged 85 and older is projected to increase from 951,833 in 2025 to 3.3-4.2 million by 2075, strengthening long-term demand for geriatric medicines and age-related healthcare.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific geriatric medicine market is expected to grow at a CAGR of 8.91% during 2026-2034, supported by rapid population ageing, with UN ESCAP projecting the region’s population aged 65 and older to increase from 516 million in 2025 to 19.4% of the total population by 2050, while WHO’s South-East Asia strategy targets stronger healthy-ageing services through 2030, expanding demand for geriatric medicines and age-related healthcare.
The Japan geriatric medicine market will see sustained demand from advanced population ageing, with Japan’s Cabinet Office projecting the population aged 65 and older to reach 39.53 million by 2043, while the share of people aged 75 and older is projected to reach 25.1% by 2070, expanding the need for medicines targeting age-related diseases and chronic conditions. The China geriatric medicine market will benefit from a rapidly expanding elderly population, with China’s government projecting the number of people aged 60 and older to exceed 400 million around 2035, up from 323.38 million at the end of 2025, increasing demand for geriatric medicines and long-term care therapies.
The South Korea geriatric medicine market will gain from continued demographic ageing, with Statistics Korea projecting the population aged 65 and older to reach 12.69 million by 2030, while the country’s total population is projected to decline to 51.31 million by 2030, increasing the proportion of older adults and demand for age-related healthcare and medicines. The India geriatric medicine market will expand alongside a larger elderly population, with the Government of India projecting people aged 60 and older to reach 230 million by 2036, representing 14.9% of the total population, increasing the patient base for chronic-disease management and geriatric medicines.
The Europe geriatric medicine market accounted for a regional share of 22.35% in 2025, supported by accelerating population ageing, with the European Commission projecting people aged 65 and above to represent around 30% of the EU population by 2050, compared with around 20% today, while the old-age dependency ratio is projected to increase from 38% in 2025 to 55.2% by 2050, expanding demand for geriatric medicines and age-related healthcare.
The UK geriatric medicine market will benefit from demographic ageing, with the latest available ONS projections indicating that people aged 65 and over will account for 23.9% of the UK population by 2036, while the number of people aged 85 and over is projected to reach 5.1 million by 2066, expanding demand for medicines targeting age-related and chronic conditions. The France geriatric medicine market will see a larger elderly patient base, with INSEE projecting the population aged 65 and over to increase by 5.8 million between 2026 and 2070, reaching 32% of the population by 2070, while the number of people aged 80 and over is expected to rise by 4.6 million, strengthening long-term demand for geriatric medicines.
The Germany geriatric medicine market will gain from continued demographic ageing, with Destatis projecting the population aged 67 and over to reach at least 20.5 million by the end of the 2030s, while this group is expected to represent 24%-27% of Germany’s population by 2040 across its main projection variants, expanding demand for age-related medicines and chronic-disease management.
The geriatric medicine market is fragmented, with multinational pharmaceutical companies, generic-drug manufacturers, specialty pharmaceutical firms, biotechnology companies, contract development and manufacturing organizations, and regional healthcare companies serving older adults across chronic disease, cardiovascular, neurological, metabolic, oncology, and other age-associated conditions. Pfizer, Novartis, AstraZeneca, Merck & Co., and Sanofi collectively account for approximately 22% of the global geriatric medicine market share in 2025.
Established players compete on clinical evidence, physician relationships, distribution networks, and pricing, while emerging and regional players in the geriatric medicine market ecosystem compete through affordable generics, localized manufacturing, flexible supply, and niche therapeutic applications. The competitive environment is also shaped by the specific medication needs of older adults, including age-related changes in drug absorption and elimination and the higher risk of drug interactions, which increase the importance of formulation, safety, and clinical support.
July 2025: Research into agentic AI for elderly care highlighted opportunities to use AI for personalized health tracking, cognitive care, and environmental support for older adults.
September 2025: The National Centre of Ageing at Banaras Hindu University was nearing completion, with planned specialized services including memory clinics, fall-prevention programs, rehabilitation, and multidisciplinary geriatric care.
February 2026: New market analysis highlighted continued expansion of geriatric medicines, supported by the rising elderly population and increasing prevalence of cardiovascular and other chronic diseases.
March 2026: The Indian government reported that the population aged 60 years and above is projected to rise to 23 crore by 2036, strengthening the long-term need for specialized geriatric healthcare and medicines.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Head
Ismail Sutaria is a market intelligence and strategy professional with over 12 years of experience advising organizations across the chemicals, packaging, industrial machinery, and energy & power sectors. He specializes in delivering data-driven market assessments, commercial due diligence, industry benchmarking, demand forecasting, competitive strategy, and growth advisory that enable businesses to make confident investment and expansion decisions in complex industrial markets.
His expertise spans specialty and commodity chemicals, advanced and sustainable packaging solutions, industrial automation, manufacturing equipment, process engineering, renewable energy, conventional power generation, electrical infrastructure, and industrial technologies. Ismail has developed deep domain knowledge in evaluating market ecosystems, technology evolution, regulatory frameworks, supply-demand dynamics, pricing trends, value chain structures, and competitive landscapes across global and regional markets.
Welding Market Size, Share, Growth, Analysis, Report, 2034
Greasing System Market Size, Share, Growth, Analysis, Report, 2034
Ball Valve Market Size, Share, Growth, Analysis, Report, 2034
Fluid Dispensing Equipment Market Size, Share, Growth, Analysis, 2034
Inspection Machines Market Size, Share, Growth, Analysis, 2034
Fans and Blowers Market Size, Share, Growth, Forecast, 2034
We are featured on:
sales@straitsresearch.com